Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly immune-suppressive tumor with a low response rate to single checkpoint blockade therapy. ETS homologous factor (EHF) is a tumor suppressor in PDAC. Here, we report a novel function of EHF in pancreatic cancer immune microenvironment editing and eff...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Exp Med
Autori principali: Liu, Jing, Jiang, Wenna, Zhao, Kaili, Wang, Hongwei, Zhou, Tianxing, Bai, Weiwei, Wang, Xiuchao, Zhao, Tiansuo, Huang, Chongbiao, Gao, Song, Qin, Tai, Yu, Wenwen, Yang, Bo, Li, Xin, Fu, Danqi, Tan, Wei, Yang, Shengyu, Ren, He, Hao, Jihui
Natura: Artigo
Lingua:Inglês
Pubblicazione: Rockefeller University Press 2019
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6400540/
https://ncbi.nlm.nih.gov/pubmed/30733283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20180749
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi